Sanofi (SNY) – What Are Brokerages Saying About This Stock?

Sanofi (NASDAQ:SNY) has earned an average recommendation of “Hold” from the twenty-one analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $49.50.

A number of brokerages have weighed in on SNY. HSBC reiterated a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Wolfe Research started coverage on shares of Sanofi in a research report on Friday, October 9th. They set a “peer perform” rating on the stock. DZ Bank restated a “buy” rating on shares of Sanofi in a research report on Friday, July 31st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a report on Thursday, October 1st. Finally, UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Manning & Napier Advisors LLC grew its position in Sanofi by 728,134.8% during the 1st quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock worth $57,542,000 after purchasing an additional 1,194,141 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Sanofi by 11.0% in the first quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after buying an additional 940,342 shares during the last quarter. Regal Partners Ltd raised its holdings in shares of Sanofi by 33.2% in the first quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock valued at $122,639,000 after buying an additional 633,782 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Sanofi by 17.5% during the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock worth $152,011,000 after buying an additional 470,882 shares during the period. Finally, ADAR1 Capital Management LLC boosted its stake in shares of Sanofi by 399.3% during the first quarter. ADAR1 Capital Management LLC now owns 316,939 shares of the company’s stock worth $15,270,000 after buying an additional 253,465 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Up 0.8%

Shares of NASDAQ SNY opened at $40.61 on Friday. The stock has a market cap of $98.46 billion, a PE ratio of 21.26, a price-to-earnings-growth ratio of 1.24 and a beta of 0.33. The company has a quick ratio of 0.64, a current ratio of 0.99 and a debt-to-equity ratio of 0.21. Sanofi has a 52-week low of $39.07 and a 52-week high of $52.68. The business has a 50-day moving average price of $42.68 and a 200 day moving average price of $43.79.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The firm had revenue of $13.36 billion for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.24 EPS. Equities research analysts forecast that Sanofi will post 5.00 earnings per share for the current year.

Sanofi Company Profile

Sanofi is a France-based global healthcare company that develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. Its portfolio focuses on areas including immunology, rare diseases, vaccines, diabetes and other chronic conditions, as well as specialized treatments for selected neurological and inflammatory disorders.

The company is known for products such as Dupixent, a biologic used to treat several inflammatory conditions, and a broad range of vaccines marketed through its Sanofi Pasteur business.